ORIGINAL RESEARCH

Synthesis and Identification of a Novel Peptide, Ac-SDK (Biotin) Proline, That Can Elicit Anti-Fibrosis Effects in Rats Suffering from Silicosis

This article was published in the following Dove Press journal: Drug Design, Development and Therapy

Background: N-Acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a short peptide with an anti-silicosis effect. However, the short biological half-life and low plasma concentration of Ac-SDKP hamper discovery of specific targets in organisms and reduce the anti-silicosis effect. A novel peptide, Ac-SDK (biotin) proline, termed "Ac-B", with anti-fibrotic properties was synthesized.

Methods: Ac-B was detected quantitatively by high-performance liquid chromatography. Phagocytosis of Ac-B by the alveolar epithelial cell line A549 was investigated by confocal laser scanning microscopy and flow cytometry. To further elucidate the cellular-uptake mechanism of Ac-B, chemical inhibitors of specific uptake pathways were used. After stimulation with transforming growth factor- β 1, the effects of Ac-B on expression of the myofibroblast marker vimentin and accumulation of collagen type I in A549 cells were analyzed by Western blotting. Sirius Red staining and immunohistochemical analyses of the effect of Ac-B on expression of α -smooth muscle actin (SMA) in a rat model of silicosis were undertaken.

Results: Ac-B had good traceability during the uptake, entry, and distribution in cells. Ac-B treatment prevented an increase in α -SMA expression in vivo and in vitro and was superior to that of Ac-SDKP. Caveolae-mediated uptake of Ac-B by A549 cells led to achieving anti-epithelial–mesenchymal transformation (EMT) effects.

Conclusion: Ac-B had an anti-fibrotic effect and could be a promising agent for the fibrosis observed in silicosis in the future.

Keywords: Ac-SDKP, biotin, epithelial-mesenchymal transformation, phagocytosis, antifibrotic function

Plain Language Summary

N-Acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a short peptide with anti-fibrotic effects. However, the short biological half-life and low plasma concentration of Ac-SDKP make it difficult to find specific targets in organisms and reduce the anti-silicosis fibrosis effect. In our study, a novel visual peptide Ac-SDK (biotin) P [Ac-B] with anti-fibrotic properties was synthesized. It showed good traceability during the processes of cellular uptake, entry, and distribution. Both in vivo and in vitro results indicate that Ac-B has an anti-EMT effect to prevent the progress of silicosis fibrosis. The uptake of Ac-B by endothelial cells occurred via a caveolae-mediated pathway to achieve anti-EMT effects. The good traceability of Ac-B may could ensure its use as a promising agent for anti-silicosis fibrosis therapy and to investigate the distribution, metabolism, and target sites of Ac-B in vivo in animal experiments.

Drug Design, Development and Therapy 2020:14 4315-4326

4315

Jin Wang^{1,2} Ye Qian² Xuemin Gao³ Na Mao³ Yucong Geng⁴ Gaojie Lin³ Guibin Zhang² Han Li³ Fang Yang³ Hong Xu³

¹Department of Clinical Laboratory, Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai 201700, People's Republic of China; ²Hebei Key Laboratory for Chronic Diseases, Tangshan Key Laboratory for Preclinical and Basic Research on Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, Hebei 063210, People's Republic of China; ³Medical Research Center, International Science and Technology Cooperation Base of Geriatric Medicine, North China University of Science and Technology, Tangshan, Hebei 063210, People's Republic of China; ⁴Department of Pathology, Haigang Hospital of Qinhuangdao, Qinhuangdao, Hebei, 066000, People's Republic of China

Correspondence: Hong Xu Medical Research Center, International Science and Technology Cooperation Base of Geriatric Medicine, North China University of Science and Technology, Tangshan, Hebei 063210, People's Republic of China Tel +86-315-8816236 Fax +86-315-8816238 Email xuhong@ncst.edu.cn



© 2020 Wang et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. bp and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0). License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission foro Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

Introduction

Silicosis is a severe pneumoconiosis caused by long-term inhalation of large amounts of crystalline silica dust in mining or other dusty occupational environments.¹ Due to the complex mechanism of its occurrence, curative treatment for silicosis is lacking.²

N-Acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a tetrapeptide with anti-fibrotic effects. It is secreted from bone marrow, and has been found to inhibit proliferation of pluripotent hematopoietic stem cells.³ Prolyl oligopeptidase is responsible for the release of Ac-SDKP from its precursor, thymosin-β4.⁴ Research involving injury to the heart,⁵ kidney,⁶ lung,⁷ and brain⁸ has shown that Ac-SDKP treatment ameliorates end-organ damage (at least in part) by inhibiting collagen deposition in target organs. Also, Ac-SDKP treatment has been shown to reduce the extent of organ fibrosis caused by pathogenic factors, such as myocardial infarction,⁹ diabetic renal fibrosis,¹⁰ renal injury,¹¹ interstitial lung disease induced by bleomycin,¹² liver damage induced by bile-duct ligation,¹³ and silicosis,^{11,14,15} in several animal models.

In vitro studies have shown that Ac-SDKP can inhibit the proliferation and collagen synthesis/expression, especially of cardiac fibroblasts, pulmonary fibroblasts, and glomerular mesangial cells.^{16–18} Therefore, Ac-SDKP is a potential drug for the treatment of fibrosis in vivo and in vitro.

Angiotensin-converting enzyme (ACE)-1 is a zinc dipeptidyl carboxypeptidase with two active domains. It plays a key part in regulation of blood pressure and electrolyte homeostasis. Ac-SDKP has a short biological half-life and low plasma concentration. Ac-SDKP is processed exclusively by ACE-1.¹⁹ Ac-SDKP is a polypeptide drug composed of common amino acids without unusual side-chains, which hampers quantitative detection in vivo. Thus, the clinical application of Ac-SDKP is limited.

Biotin, also named "vitamin H", is a small molecule. It can be coupled to many proteins or peptide macromolecules without obvious influence on its physical, and chemical properties or biological activity. Avidin (molecular weight of its tetrameric form is 66–69 kDa) can bind to tetramolecular biotin, and the affinity between them is extremely strong and irreversible. The dissociation constant of the avidin–biotin complex is 10–15 mol/L. The avidin–biotin system plays an important part in the recognition, interaction, purification, detection, fixation, and labeling of molecules.^{20–23} A peptide, Ac-SDK (biotin) proline, which was termed "Ac-B", was prepared by the fusion of biotin and Ac-SDKP via chemical synthesis. The anti-epithelial–mesenchymal transformation (EMT) and anti-fibrotic effects of Ac-B were investigated in vivo and in vitro, respectively. Its good traceability was characterized by exploring its uptake, entry, and distribution in cells. Sustained release of Ac-B in vitro was studied by real-time quantitative detection of Ac-B. The good traceability of Ac-B could aid anti-fibrosis therapy in silicosis, as well as to investigate the distribution, metabolism, and target sites of Ac-B in vivo in animals.

Materials and Methods Chemicals and Reagents

The high-performance liquid chromatography (HPLC) system was the 1200 series (Agilent Technologies, Santa Clara, CA, USA) with a UV detector and column (XDB-C18, 4.6×15 cm; particle size, 5 µm; Agilent Technologies). The UV spectrophotometer (UV-2450) was from Shimadzu (Kyoto, Japan). The pH meter (PB10) was from Sartorius (Göttingen, Germany). Water was prepared using the Milli-Q[®] system (Millipore, Bedford, MA, USA).

Ac-Ser-Asp-Lys (biotin)-Pro (Ac-B; molecular weight 713.79) was synthesized by Shanghai Qiangyao Biotechnology (Shanghai, China).

Acetonitrile and trifluoroacetic acid were of chromatography grade and purchased from Sinopharm Chemical Reagents (Shanghai, China). Phosphate-buffered saline (PBS), Dulbecco's modified Eagle's medium (DMEM), and fetal calf serum were obtained from HyClone (Jülich, Germany). Surfactant protein A (SP-A) was purchased from Beijing Bioss Biotechnology (Beijing, China). Vimentin, α -smooth muscle actin (SMA) and transforming growth factor (TGF)-B1 were obtained from PeproTech (Rocky Hill, NJ, USA). Collagen type I was purchased from Genetec (Montreal, Canada). Tubulin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were obtained from Affinity Biotech (Cincinnati, OH, USA). Dynasore was purchased from Aladdin (Beijing, China). Mycostatin was obtained from Haoranbio (Beijing, China). Streptavidin/ RBITC was purchased from Solarbio (Beijing, China).

Analyses of Ac-B by HPLC

Ac-B (10 μ M) was subjected to HPLC using the system and column mentioned above. The column was developed at a flow rate of 1 mL/min with a solvent gradient using 0.03% trifluoroacetic acid in water (solvent A) and

acetonitrile (solvent B): 20–80% B over 10 min. The absorbance at 210 nm was measured using the UV spectrophotometer.

Cell Culture and Experimental Grouping

The human type II alveolar epithelial A549 cell lines purchased from the Chinese Academy of Sciences cell library (TCHu150, Shanghai, China) were cultured and maintained in RPMI 1640 medium containing 10% fetal bovine serum in an atmosphere of 5% CO₂ at 37°C. A549 cells were seeded into six-well plates when confluence reached 50–65% (\sim 5×10⁴ cells). Cells were incubated in medium without serum for 24 h.

Four experimental groups were created: control (cultured in RPMI 1640 without serum for 24 h); TGF- β 1 induction (cultured in serum-free RPMI 1640 and stimulated by TGF- β 1 (5 µg/L) for 24 h); Ac-SDKP drug intervention (TGF- β 1 +Ac-SDKP; under culture with serum-free RPMI 1640, cells were first induced with Ac-SDKP (10⁻⁸ mol/L) and then incubated with TGF- β 1 (5 µg/L) for 24 h; Ac-B intervention (cells were cultured in RPMI 1640 without serum but with Ac-B (10⁻⁸ mol/L) for 1 h and then incubated with TGF- β 1 (5 µg/L) for 24 h.

Western Blotting

After induction, 20 µg of protein cell lysate was fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride (PVDF) membranes. The latter were allowed to react with antibodies against α -SMA, collagen I, vimentin, GAPDH or tubulin (1:1000 dilution), incubated overnight at 4°C, and then incubated with anti-goat anti-rabbit immunoglobulin-G (1:5000 dilution) for 30 min at 37°C. Electrochemiluminescence reagent was developed for 1 min. Image-Pro Plus (Media Cybernetics, San Diego, CA, USA) was used to analyze protein bands. The ratio of the target protein to the absorbance of the reference protein was taken as the relative expression of the protein.

Cell Phagocytosis

The efficiency of Ac-B accumulation in A549 cells was analyzed by laser scanning confocal microscope (LSCM) system (Olympus FV1200). Ac-B was configured to 1 mg/ mL. After three generations, A549 cells were trypsinized to form a suspension, and 2 mL of an A549 cell suspension ($\sim 2 \times 10^5$ cells) was inoculated for LSCM. The final concentration of Ac-B was set to 40 µg/mL per well in a special LSCM culture dish that had been incubated at

37°C, and three replicates were set. Ac-B uptake by A549 cells was observed by sequential LSCM at 0, 5, 15, 30, 60 and 120 min. Cell cultures were fixed and labeled with fluorescence-conjugated Streptavidin/RBITC. Treated A549 cells were washed three times with PBS and harvested by trypsinization for quantitative characterization. After centrifugation, cell pellets were washed once and resuspended with PBS buffer. The cellular uptake of Ac-B was quantitatively determined by flow cytometry. The experiment was carried out in triplicate, and the mean value was calculated.

Mechanisms of Ac-B Uptake by Cells

The cellular-uptake mechanisms of Ac-B were investigated by blocking the uptake pathway with different treatments. To block energy-dependent endocytosis, cells were preincubated with NaN₃ (10 mM) in PBS for 30 min at 37°C to deplete adenosine triphosphate. To block the clathrinmediated pathway by hypertonic treatment, cells were preincubated for 30 min with sucrose (0.45 M) in PBS at 37°C. To inhibit clathrin-mediated endocytosis and ultrafast endocytosis at a late stage of vesicle scission, cells were preincubated for 30 min with dynasore (80 µM) in PBS at 37°C. Clathrin regenerates synaptic vesicles from endosomes. In addition, cells were pretreated with mycostatin (5 mg/mL) in PBS for 30 min to block the caveolae-mediated pathway. Afterwards, all of the cells mentioned above were washed twice with PBS and incubated with Ac-B (1 mg/mL) in serum-free medium for 2 h at 37°C. After washing several times with PBS, treated cells were observed by fluorescence microscopy. Treated cells were washed thrice with PBS and harvested by trypsinization for quantitative characterization. After centrifugation, cell pellets were washed and resuspended in PBS. Cellular uptake of Ac-B was determined quantitatively by flow cytometry. The experiment was carried out in triplicate and the mean value calculated.

Creation of a Silicosis Model in Rats

Animal-related procedures were undertaken according to protocols approved by the Animal Care and Use Committee of North China University of Science and Technology (2016–0001) in Tangshan, China. Animals received food and water according to guidelines set by the National Institutes of Health (Bethesda, MD, USA).

Male Wistar rats (180±10 g; 6–8-weeks old) were purchased from Vital River Laboratory Animal Technology Co. Ltd. (catalog number, SCXY 2009–0004; Beijing, China).

4317

The silicon dioxide we utilized (purity: 99%, particle size: <5 µm) was purchased from Sigma-Aldrich (Saint Louis, MO, USA). Wistar rats were anesthetized with isoflurane. Their tracheae were exposed to a SiO₂ solution (50 mg/mL per rat) or physiologic (0.9%) saline (as vehicle control). Ac-SDKP (800 µg/kg·day; Bachem, Geneva, Switzerland) or the vehicle control was administered (ip) for 4 weeks. Rats were divided into four groups: control 4 weeks (instilled with 0.9% saline and then administered 0.9% saline for 4 weeks); silicosis model 4 weeks (instilled with SiO_2 and then administered 0.9% saline for 4 weeks); Ac-SDKP anti-fibrosis (instilled with SiO₂, treated with 0.9% saline for 4 weeks, and then Ac-SDKP for another 4 weeks); Ac-B anti-fibrosis (instilled with SiO₂, treated with 0.9% saline for 4 weeks, and then Ac-B for another 4 weeks) (Figure 1). Each experimental group comprised eight rats.

Histopathology

Lung tissues were fixed with 4% paraformaldehyde and then embedded in paraffin. Transverse sections (4 μ m) were stained with Sirius Red (Maxin, Fuzhou, China) to observe histopathologic changes and collagen deposition.

Immunohistochemical Analyses

Immunostaining was carried out on tissue sections. Briefly, 4-µm paraffin sections were deparaffinized and rehydrated, followed by conventional preparation of cell slides for immunostaining. Antigen retrieval was done by a highpressure method followed by 15 min of incubation with 0.03% H₂O₂ to block peroxidase activity. Slides were incubated with α -SMA and maintained overnight at 4°C. Subsequent steps followed the instructions from a one-step polymer-detection system kit (Genetec). Counterstaining was done using hematoxylin. Finally, slides were sealed with neutral balsam. Images were acquired by microscopy (BX53; Olympus, Tokyo, Japan).

Statistical Analyses

The data were collected and analyzed by SPSS 20.0 (Asia Analytics Formerly SPSS China). The pictures were drawn by Graphpad 8.0. The measurement results were expressed by mean±SD (standard deviation). Differences between two groups were determined by the Student's *t*-test. Differences between two or more groups were analyzed by ANOVA. The value of p < 0.05 was considered statistically significant.

Results

Ac-B Absorption

At a detection wavelength of 210 nm, biotin attachment to Ac-B was detected quantitatively by HPLC (Figure 2). A peak value was not observed for Ac-SDKP (red line in Figure 2), which suggested that Ac-SDKP could not be detected randomly by HPLC at 210 nm. In comparison, the blue line in Figure 2 shows a large peak for Ac-B, which demonstrated that biotin-containing Ac-B could be detected quantitatively by HPLC.

Phagocytic Efficiency of Ac-B in A549 Cells and the Mechanism

After biotin labeling, Ac-B accumulation in cells could be observed in real-time. Phagocytosis of Ac-B by A549 cells was investigated by LSCM (Figure 3A). At 37°C, the culture time was set as 0, 5, 15, 30, 60 and 120 min, and the phagocytotic efficiency of Ac-B in A549 cells was 0%, 12.6 $\pm 1.2\%$, 17.7 $\pm 0.5\%$, 34.7 $\pm 2.1\%$, 65.1 $\pm 2.3\%$ and 96.6 $\pm 1.9\%$, respectively (Figure 3B and C). Ac-B uptake by A549 cells was correlated positively with time on the basis of qualitative



Figure I Silicosis model and treatment scheme. Wistar rats were anesthetized with isoflurane and their tracheae were exposed to a SiO_2 solution (50 mg/mL per rat) or physiologic (0.9%) saline (vehicle control). They were administered via the intraperitoneal route using the treatment scheme as shown with 0.9% saline, Ac-SDKP, and Ac-B for 4 weeks. Detecting markers of pulmonary fibrosis.



Figure 2 Chromatogram of Ac-B: detection of characteristic peaks of Ac-B by HPLC under absorbance at 210 nm.

and quantitative results. These results reflected the amount of Ac-B taken into the cell after different incubation times.

Chemical inhibitors of specific uptake pathways were used to elucidate further the cellular-uptake mechanism of Ac-B. The presence of NaN₃ led to an obvious decrease in intracellular fluorescence intensity compared with that of the control group (Figure 4A), which suggested that Ac-B uptake was dependent upon energy. Cellular uptake of Ac-B was different when A549 cells were treated individually with corresponding clathrin- and caveolae-mediated endocytosis inhibitors. In particular, mycostatin could reduce Ac-B uptake by cells significantly. These results demonstrated that Ac-B tended to be internalized into cells via the caveolae-mediated pathway. Moreover, flow cytometry was used to quantify the amount of Ac-B uptake by A549 cells. Cellular uptake of Ac-B was reduced markedly (>80%) by treatment with NaN₃ at 37°C (Figures 4B and C), further demonstrating that internalization was energy-dependent endocytosis. When A549 cells were preincubated with mycostatin (5 mg/mL), uptake was reduced to 26%±2.7% compared with that of untreated cells. However, pretreatment with sucrose or dynasore did not hinder Ac-B internalization specifically. These results suggested that uptake of Ac-B nanoparticles occurred mainly via the caveolae-mediated pathway.

Effects of Ac-B on Vimentin Expression and Accumulation of Collagen Type I in A549 Cells After Stimulation with TGF- β I We demonstrated that Ac-SDKP could suppress myofibroblast differentiation from alveolar epithelial cells (A549). To detect the biological function of Ac-B, we tested the effect of Ac-B treatment on myofibroblast differentiation induced by TGF-B1 in A549 cells. Pretreatment with Ac-SDKP/Ac-B for 1 h before TGF-B stimulation could inhibit the decrease in SP-A level (Figure 5B) in epithelial cells significantly. Western blotting indicated increases in expression of markers of interstitial cells: α-SMA (Figure 5C), vimentin (Figure 5D), and collagen type I (Figure 5E). Among them, increased expression of vimentin and collagen type I stimulated by TGF-β was inhibited markedly by Ac-B pretreatment (Figure 5A).

Effects of Ac-B on α -SMA Expression in a Rat Model of Silicosis

In the silicotic model (4 weeks), cell-fibrous nodules and mass collagen deposition could be observed in silicotic lesions in rats exposed to silica for 4 weeks. The alveolar interstitium was thickened and nodules composed of

Α



Figure 3 Phagocytosis efficiency of Ac-B by A549 cells. Ac-B ($40 \mu g/mL$) uptake by A549 cells was observed by sequential laser scanning confocal microscope (**A**) and flow cytometry (**B**) at 0, 5, 15, 30, 60 and 120 min and three replicates were set. (**C**) The histograms represent the phagocytosis efficiency of Ac-B by A549 cells. Results are the mean \pm SD of three experiments. **P < 0.01.

macrophages and fibroblasts were visible. Compared with the corresponding silicosis control group, Sirius Red staining showed that the numbers of nodules was reduced and the volume of nodules was smaller with less collagen accumulation in Ac-SDKP/Ac-B treatment groups. The therapeutic effect of Ac-B was more efficacious than that of Ac-SDKP (Figure 6A and C). Furthermore, immunohistochemical staining (Figure 6B) and Western blotting (Figure 6D) showed decreased levels of α -SMA in the lungs of rats in the Ac-B group (Figure 6E).

Discussion

Although the target of the anti-pulmonary-fibrosis effect of Ac-SDKP is not clear, it has been shown to have an anti-EMT effect. EMT is a critical stage during fibrosis development in silicosis, and plays an important part in lung fibrosis.^{16,17,24,25} EMT is the process through which epithelial cells acquire the characteristics of mesenchymal cells following activation by growth factors such as TGF- $\beta 1$.^{26,27} Growth factors trigger upregulation of genes usually expressed in mesenchymal cells (eg, α -SMA,



Figure 4 Phagocytosis mechanism of Ac-B by A549 cells.(A) Fluorescence-microscopy images of A549 cells treated with Ac-B (1 mg/mL) for 2 h at 37° C (as a control) and at 37° C after pretreatment with NaN₃ (10 mM), dynasore (80 μ m) sucrose (0.45 M) or mycostatin (5 mg/mL). Red fluorescence shows the location of the Ac-B doped with biotin. Cell nuclei were stained with DAPI (blue). Flow cytometry (B) and the histograms (C) shows the cellular internalization of Ac-B after treatment with different inhibitors. Cellular uptake was normalized against control cells without inhibitor treatment. Results are the mean ± SD of three experiments. **P < 0.01.

vimentin) and downregulation of the genes expressed in epithelial cells (eg, E-cadherin, SP-A).^{28,29} Previously, we showed that Ac-SDKP protects the structure and function of type-II alveolar epithelial cells. Thus, Ac-SDKP inhibits the transition of epithelial cell–myofibroblasts via activation of a TGF- β 1/ROCK1 signaling pathway, and this is an anti-fibrotic property of Ac-SDKP.¹⁷ Recently,

we discovered that Ac-SDKP increases expression of α -TAT1 and promotes the apoptosis of lung fibroblasts and epithelial cells stimulated with TGF- β 1 and silica.³⁰ Expression of meprin A (a master regulator of Ac-SDKP),³¹ is diminished by microRNA-155-5p in silicosis and control lung macrophages and fibroblasts upon activation.³²



Figure 5 The molecular mechanism by which Ac-B exerts anti-fibrotic effects. (A) Expression of the transcription factors SP-A, vimentin, α -SMA, and collagen type I (Western blotting). Densitometric measurement of levels of collagen I type I (B), vimentin (C), α -SMA (D) and SP-A (E) normalized to the internal control and expressed as a relative number. **P < 0.01.

Ac-SDKP restricts the fibrosis seen in silicosis by eliciting anti-EMT activity. However, the short biological half-life and low plasma concentration of Ac-SDKP hamper: (i) quantitative detection in vivo; (ii) finding specific targets in organisms. Zhuo et al used ¹²⁵I-labeled 3-(p-hydroxyphenyl)-propionic acid (Hpp)-Aca-SDKP (a biologically active analog of Ac-SDKP) to detect localization of binding sites for Ac-SDKP receptors in rat cardiac fibroblasts³³ Zhang et al protected Ac-SDKP from physiologic hydroxylation through modification of d-amino acids and enhanced its anti-fibrotic effect upon liver fibrosis.³⁴ In the present study, to protect its original anti-fibrotic activity,¹⁷ biotin was labeled on the K side-chain of Ac-SDKP to form Ac-B (Figure 7A). Biotin branches cause steric hindrance, which reduces the efficiency of degradation by ACE-1, thereby increasing the Ac-B concentration in plasma.¹⁹ To detect the biological function of Ac-B, fibrosis models were constructed at cellular and animal levels, respectively. A549 cells were induced by TGF-B in vitro to construct a cell model of EMT. Western blotting showed that, compared with control treatment, TGF-B treatment decreased expression of the epithelial-cell marker SP-A significantly, and increased expression of the interstitial-cell markers a-SMA, vimentin and collagen type I, which suggested that the EMT model had been established. Vimentin controls the transfer of cholesterol from lysosomes to esterification sites while maintaining cytoskeletal stability. It is often used as a marker for mesenchymal cells. Increased expression of vimentin indicates that EMT has been accelerated. We found that Ac-B could inhibit EMT effectively, which suggested that Ac-B could also maintain/preserve epithelial cells and suppress mesenchymal cells during silicosis. Western blotting indicated that the anti-EMT effect of Ac-B was better than that observed in Ac-SDKP groups.



Figure 6 Observation of pathologic changes in a rat model of silicosis. Effects of Ac-B on the morphologic changes of lung tissue in a rat model of silicosis (**A** and **C**). Sirius Red was used to stain the lung tissues of rats from different groups, as indicated. Scale bar: 500 μ m and 50 μ m. The anti-fibrosis efficacy of Ac-SDKP and Ac-B on silicosis in rats. (**B**) Mesenchymal-cell marker (α -SMA) immunostaining (positive expression = brown). (**D**) Western blotting for α -SMA protein from treatment or non-treatment by Ac-SDKP/Ac-B. Control: control 4 weeks (instilled with 0.9% saline and then administered 0.9% saline for 4 weeks); SiO₂: silicosis model 4 weeks (instilled with SiO₂ and then administered 0.9% saline for 4 weeks); therapy group: Ac-SDKP and Ac-B anti-fibrosis respectively. Ac-SDKP anti-fibrosis (instilled with SiO₂, treated with 0.9% saline for 4 weeks), and then Ac-B for another 4 weeks); Ac-B anti-fibrosis (instilled with 5O₂, treated with 0.9% saline for 4 weeks, and then Ac-B for another 4 weeks); Ac-B anti-fibrosis (instilled with 5O₂, treated with 0.9% saline for 4 weeks, and then Ac-B for another 4 weeks). Each experimental group comprised eight rats. Repeat three control groups. (**E**) Densitometric measurement of α -SMA protein level normalized to that of the internal control, respectively, and expressed as a relative number. Data are the mean \pm SD (n = 5 per group). Statistical analyses were undertaken using one-way ANOVA. **P < 0.001 vs Ac-SDKP. (For interpretation of the references to color in this figure legend, the reader is referred to the online version of this article.).



Figure 7 (A) Chemical composition of Ac-B. The K side-chain of Ac-SDKP was modified with biotin. Biotin was labeled on the K side-chain of Ac-SDKP to form Ac-B. When biotin is combined with Streptavidin/RBITC, Ac-B is visualized. (B) Mechanism by which Ac-B inhibits fibrosis in silicosis through anti-EMT activity (schematic). Ac-B achieves an anti-EMT effect after entering into endothelial cells via caveolae-mediated endocytosis.

These results showed that this complex had excellent action against EMT (Figure 5) and good traceability, which allowed real-time quantitative detection of Ac-SDKP during uptake (Figure 3), entry, and distribution in cells. At 4 weeks in the silicosis model in rats, Ac-B restored the consequences of SiO₂-mediated fibrosis caused by silicosis (Figure 6). Ac-B was able to enter into endothelial cells via caveolae-mediated, but not clathrin-mediated, endocytosis and achieved an anti-EMT effect to stop fibrosis in silicosis (Figure 4; Figure7B). In subsequent experiments, we explored the target site of the anti-pulmonary fibrosis effects of Ac-B in a rat model of silicosis. Fibrosis associated with inhalation of silica particles is deeply related to inflammasomes and cytokines released. We will further study the effect of Ac-B on them. Explore the role of Ac-B in the treatment of other fibrotic diseases in further research.

Conclusions

Ac-B, an anti-fibrotic peptide with good traceability, was prepared via attachment of biotin to Ac-SDKP. The mechanism for the phagocytosis of Ac-B by cells was elucidated. Cell experiments and animal experiments showed that Ac-B had an anti-EMT effect to prevent the progress of fibrosis in silicosis. Ac-B uptake by endothelial cells occurred via a caveolae-mediated pathway to achieve anti-EMT effects. The good traceability of Ac-B may enable its use as an agent for anti-silicosis therapy, as well as to investigate the distribution, metabolism and target sites of Ac-B in vivo in animals.

Data Sharing Statement

The data used to support the findings of this study are available from the corresponding author upon request.

Author Contributions

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

Funding

This work was supported financially by the National Natural Science Foundation of China (31800715), Natural Science Foundation of Hebei Province (H2017209190), Department of Science and Technology of Hebei Province (16272707), Health and Family Planning Commission of Hebei Province (20170888) and the North China University of Science and Technology Outstanding Youth Science Foundation.

Disclosure

The authors report no conflicts of interest in this work.

References

 Franklin BS, Mangan MS, Latz E. Crystal formation in inflammation. *Annu Rev Immunol*. 2016;34:173–202. doi:10.1146/annurev-immunol -041015-055539

- 2. Leung CC, Yu IT, Chen W. Silicosis. *Lancet.* 2012;379 (9830):2008–2018. doi:10.1016/S0140-6736(12)60235-9
- Thierry J, Grillon C, Gaudron S, Potier P, Riches A, Wdzieczak-Bakala J. Synthesis and biological evaluation of analogues of the tetrapeptide N-Acetyl-Ser-Asp-Lys-Pro (AcSDKP), an inhibitor of primitive haematopoietic cell proliferation. *J Pept Sci.* 2001;7 (5):284–293. doi:10.1002/psc.322
- Cavasin MA, Liao TD, Yang XP, Yang JJ, Carretero OA. Decreased endogenous levels of Ac-SDKP promote organ fibrosis. *Hypertension*. 2007;50(1):130–136.
- Sharma UC, Sonkawade SD, Spernyak JA, et al. A small peptide Ac-SDKP inhibits radiation-induced cardiomyopathy. *Circ Heart Fail.* 2018;11(8):e004867. doi:10.1161/CIRCHEARTFAILURE. 117.004867
- Romero CA, Kumar N, Nakagawa P, et al. Renal release of N-acetylseryl-aspartyl-lysyl-proline is part of an antifibrotic peptidergic system in the kidney. *Am J Physiol Renal Physiol.* 2019;316(1):F195– F203. doi:10.1152/ajprenal.00270.2018
- Zhang B, Xu H, Zhang Y, et al. Targeting the RAS axis alleviates silicotic fibrosis and Ang II-induced myofibroblast differentiation via inhibition of the hedgehog signaling pathway. *Toxicol Lett.* 2019;313:30–41. doi:10.1016/j.toxlet.2019.05.023
- Pejman S, Kamarehei M, Riazi G, Pooyan S, Balalaie S. Ac-SDKP ameliorates the progression of experimental autoimmune encephalomyelitis via inhibition of ER stress and oxidative stress in the hippocampus of C57BL/6 mice. *Brain Res Bull.* 2020;154:21–31. doi:10.1016/j.brainresbull.2019.09.014
- Ntsekhe M, Matthews K, Wolske J, et al. Scientific letter: ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) and galectin-3 levels in tuberculous pericardial effusion: implications for pathogenesis and prevention of pericardial constriction. *Heart.* 2012;98(17):1326–1328. doi:10.1136/heartjnl-2012-302196
- Yang F, Yang XP, Liu YH, et al. Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. *Hypertension*. 2004;43(2):229–236. doi:10.1161/01.HYP.0000107777. 91185.89
- Zhang L, Xu LM, Chen YW, et al. Antifibrotic effect of N-acetylseryl-aspartyl-lysyl-proline on bile duct ligation induced liver fibrosis in rats. *World J Gastroenterol.* 2012;18(37):5283–5288.
- Srivastava SP, Shi S, Kanasaki M, et al. Effect of antifibrotic MicroRNAs crosstalk on the action of N-acetyl-seryl-aspartyl-lysylproline in diabetes-related kidney fibrosis. *Sci Rep.* 2016;6:29884. doi:10.1038/srep29884
- Worou ME, Liao TD, D'Ambrosio M, et al. Renal protective effect of N-acetyl-seryl-aspartyl-lysyl-proline in dahl salt-sensitive rats. *Hypertension*. 2015;66(4):816–822. doi:10.11 61/HYPERTENSIONAHA.115.05970
- 14. Zhang L, Xu D, Li Q, et al. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) attenuates silicotic fibrosis by suppressing apoptosis of alveolar type II epithelial cells via mediation of endoplasmic reticulum stress. *Toxicol Appl Pharmacol.* 2018;350:1–10. doi:10.1016/j. taap.2018.04.025
- Xu H, Yang F, Sun Y, et al. A new antifibrotic target of Ac-SDKP: inhibition of myofibroblast differentiation in rat lung with silicosis. *PLoS One.* 2012;7(7):e40301. doi:10.1371/journal.pone.0040301
- Deng H, Yang F, Xu H, et al. Ac-SDKP suppresses epithelial-mesenchymal transition in A549 cells via HSP27 signaling. *Exp Mol Pathol*. 2014;97(1):176–183. doi:10.1016/j.yexmp.2014.07.003
- Deng H, Xu H, Zhang X, et al. Protective effect of Ac-SDKP on alveolar epithelial cells through inhibition of EMT via TGF-beta1/ ROCK1 pathway in silicosis in rat. *Toxicol Appl Pharmacol*. 2016;294:1–10. doi:10.1016/j.taap.2016.01.010
- Ma X, Yuan Y, Zhang Z, Zhang Y, Li M. An analog of Ac-SDKP improves heart functions after myocardial infarction by suppressing alternative activation (M2) of macrophages. *Int J Cardiol.* 2014;175 (2):376–378. doi:10.1016/j.ijcard.2014.05.016

- Masuyer G, Douglas RG, Sturrock ED, Acharya KR. Structural basis of Ac-SDKP hydrolysis by angiotensin-I converting enzyme. *Sci Rep.* 2015;5:13742. doi:10.1038/srep13742
- 20. Fujii S, Mori S, Kagechika H, Mendoza Parra MA, Gronemeyer H. Development of biotin-retinoid conjugates as chemical probes for analysis of retinoid function. *Bioorg Med Chem Lett.* 2018;28 (14):2442–2445. doi:10.1016/j.bmcl.2018.06.011
- Lin WZ, Chen YH, Liang CK, Liu CC, Hou SY. A competitive immunoassay for biotin detection using magnetic beads and gold nanoparticle probes. *Food Chem.* 2019;271:440–444. doi:10.1016/j. foodchem.2018.07.152
- Ohmuro-Matsuyama Y, Yamashita T, Gomi K, Yamaji H, Ueda H. Evaluation of protein-ligand interactions using the luminescent interaction assay FlimPIA with streptavidin-biotin linkage. *Anal Biochem.* 2018;563:61–66. doi:10.1016/j.ab.2018.10.010
- 23. Kojima N, Suda T, Kurinomaru T, Kurita R. Immobilization of DNA with nitrogen mustard-biotin conjugate for global epigenetic analysis. *Anal Chim Acta*. 2018;1043:107–114. doi:10.1016/j.aca.2018.09.008
- 24. Qian W, Cai X, Qian Q Sirt1 antisense long non-coding RNA attenuates pulmonary fibrosis through sirt1-mediated epithelial-mesenchymal transition. *Aging (Albany NY)*. 2020;12(5):4322–4336. doi:10.18632/ aging.102882
- Zuo H, Trombetta-Lima M, Heijink IH, et al. A-kinase anchoring proteins diminish TGF-beta1/cigarette smoke-induced epithelial-to-mesenchymal transition. *Cells*. 2020;9(2):356. doi:10.3390/cells9020356
- 26. Zhang K, Fan C, Cai D, et al. Contribution of TGF-beta-mediated NLRP3-HMGB1 activation to tubulointerstitial fibrosis in rat with angiotensin ii-induced chronic kidney disease. *Front Cell Dev Biol.* 2020;8:1. doi:10.3389/fcell.2020.00001
- 27. Song L, Chen TY, Zhao XJ, et al. Pterostilbene prevents hepatocyte epithelial-mesenchymal transition in fructose-induced liver fibrosis through suppressing miR-34a/Sirt1/p53 and TGF-beta1/Smads signalling. *Br J Pharmacol.* 2019;176(11):1619–1634. doi:10.1111/ bph.14573

- 28. Jung J, Lee YJ, Choi YH, Park EM, Kim HS, Kang JL. Gas6 prevents epithelial-mesenchymal transition in alveolar epithelial cells via production of PGE2, PGD2 and their receptors. *Cells*. 2019;8(7):643. doi:10.3390/cells8070643
- 29. Liu P, Zhang B, Chen Z, et al. m(6)A-induced lncRNA MALAT1 aggravates renal fibrogenesis in obstructive nephropathy through the miR-145/FAK pathway. *Aging (Albany NY)*. 2020;12(6):5280–5299. doi:10.18632/aging.102950
- 30. Shifeng L, Hong X, Xue Y, et al. Ac-SDKP increases alpha-TAT 1 and promotes the apoptosis in lung fibroblasts and epithelial cells double-stimulated with TGF-beta1 and silica. *Toxicol Appl Pharmacol.* 2019;369:17–29. doi:10.1016/j.taap.2019.02.015
- 31. Kumar N, Nakagawa P, Janic B, et al. The anti-inflammatory peptide Ac-SDKP is released from thymosin-beta4 by renal meprin-alpha and prolyl oligopeptidase. *Am J Physiol Renal Physiol.* 2016;310(10): F1026–F1034. doi:10.1152/ajprenal.00562.2015
- Chen Y, Xu D, Yao J, et al. Inhibition of miR-155-5p exerts anti-fibrotic effects in silicotic mice by regulating meprin alpha. *Mol Ther Nucleic Acids*. 2020;19:350–360. doi:10.1016/j.omtn.2019.11.018
- 33. Zhuo JL, Carretero OA, Peng H, et al. Characterization and localization of Ac-SDKP receptor binding sites using ¹²⁵I-labeled Hpp-Aca-SDKP in rat cardiac fibroblasts. *Am J Physiol Heart Circ Physiol.* 2007;292(2):H984–H993. doi:10.1152/ajpheart.00776.2006
- 34. Zhang X, Zhou J, Zhu Y, et al. d-amino acid modification protects N-Acetyl-seryl-aspartyl-lysyl-proline from physiological hydroxylation and increases its antifibrotic effects on hepatic fibrosis. *IUBMB Life*. 2019;71(9):1302–1312. doi:10.1002/iub.2037

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peerreviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www. dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/drug-design-development-and-therapy-journal